Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Shares of Arcosa are up 0.17% at $146.75. The company is worth $7.21B, number 1738 out of 2132 on our list.
Shares are at a 52-week high, after a year that ran from $88.97 to $147.00. Holders are ahead 60.9% over twelve months, and up 1.4% across the last three months.
On the chart it holds above both the 50-day ($145.50) and 200-day ($127.31) moving averages; RSI is 66, and the last 30 sessions moved at roughly 2% annualized volatility.
Valuation works out to 14.7 times trailing earnings.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 2132 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ACA is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +0.6% | Bullish |
| Price vs 50-day average | +0.9% | Bullish |
| Price vs 200-day average | +15.3% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 66.5 | Bullish |
| MACD (12,26,9) | 0.40 | Bullish |
| Bollinger band position | 83% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 8:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 2,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$146.75 is the latest print for ACA, a move of +0.17% against yesterday's close of $146.50. Today's low and high so far: $146.53 and $146.89.
Equity value comes to $7.21B at the current price. By that measure it is number 1738 of the 2132 names in our coverage.
Buyers pay 14.7 times the last twelve months of profit (EPS $4.24).
The year's floor is $88.97 and the ceiling $147.00. Shares are 0.2% away from that ceiling.
It does. Payouts over the past twelve months work out to a 0.14% yield.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ACA.